⚯ Click on each item to view
⚯ Zhu S, Gilbert JC, Hatala P, et al. The development and characterization of a long acting anti-thrombotic von Willebrand factor (VWF) aptamer. J Thromb Haemost. 2020; 18: 1113–1123.
⚯ Zhu S, Gilbert JC, Liang Z, et al. Potent and rapid reversal of the von Willebrand factor inhibitor aptamer BT200. J Thromb Haemost. 2020; 18: 1695– 1704.
⚯ Kovacevic KD, Grafeneder J, Schörgenhofer C, et al. The von Willebrand Factor A-1 domain binding aptamer BT200 elevates plasma levels of VWF and Factor VIII: a first-in-human trial. Haematologica. 2022; 107(9): September, 2022.
⚯ Cécile V. Denis and Peter J. Lenting. How to keep the FVIII/VWF complex in the circulation. Haematologica. 2022; 107(9): 2011–2013.
⚯ Ay C, Pabinger IP, Kovacevic KD, et al. The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease. Blood Adv. 2022; 6(18): 5467-5476.
⚯ Ay C, Kovacevic KD, Kraemmer D, et al. von Willebrand Factor-binding aptamer rondoraptivon pegol as treatment for severe and non-severe hemophilia A. Blood. 2022.
BT200, a novel von Willebrand Factor (vWF) binding aptamer for bleeding disorders. Zhu S, et al TIDES Europe 2021.
Aptamer-Drug Conjugates (ApDC’s): Using the “chemical antibody” to target cancer biomarkers and kill tumor cells. Christina M, Novel Format Conjugates Summit 2022.
© 2022 Guardian Therapeutics. All rights reserved.
Headquarters
Guardian Therapeutics
101 Hartwell Avenue
Suite 2
Lexington, MA 02421
+1 (781) 918-6580
General Inquiries:
info@guardian-rx.com
Business Development Inquiries: businessdevelopment@guardian-rx.com